Citigroup Issues Positive Forecast for Haemonetics (NYSE:HAE) Stock Price

Haemonetics (NYSE:HAE) had its target price raised by equities researchers at Citigroup from $123.00 to $149.00 in a note issued to investors on Friday, Benzinga reports. The brokerage currently has a “buy” rating on the medical instruments supplier’s stock. Citigroup‘s price objective points to a potential upside of 24.30% from the company’s previous close.

A number of other analysts also recently weighed in on the company. BTIG Research increased their price objective on Haemonetics from $130.00 to $142.00 and gave the company a “buy” rating in a report on Thursday. Mizuho set a $165.00 target price on Haemonetics in a report on Thursday. Wall Street Zen upgraded Haemonetics from a “buy” rating to a “strong-buy” rating in a research report on Saturday, August 8th. Robert W. Baird increased their price target on Haemonetics from $96.00 to $119.00 and gave the company an “outperform” rating in a research note on Friday, August 21st. Finally, Weiss Ratings upgraded Haemonetics from a “hold (c-)” rating to a “hold (c)” rating in a research report on Tuesday, August 11th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $121.00.

Haemonetics Trading Down 3.4%

NYSE HAE traded down $4.24 on Friday, hitting $119.87. The company’s stock had a trading volume of 799,464 shares, compared to its average volume of 811,712. The company has a quick ratio of 1.91, a current ratio of 3.08 and a debt-to-equity ratio of 1.40. Haemonetics has a 1-year low of $51.00 and a 1-year high of $132.00. The company’s 50-day moving average is $111.18 and its 200 day moving average is $79.80. The firm has a market cap of $5.45 billion, a PE ratio of 58.76, a PEG ratio of 2.55 and a beta of 0.63.

Haemonetics (NYSE:HAE) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $1.35 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.29 by $0.06. The firm had revenue of $357.76 million during the quarter, compared to the consensus estimate of $345.15 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.27 earnings per share. As a group, analysts predict that Haemonetics will post 5.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

A number of hedge funds have recently bought and sold shares of HAE. Bank of America Corp DE acquired a new position in Haemonetics in the second quarter valued at $33,326,000. Assenagon Asset Management S.A. boosted its position in Haemonetics by 1,191.9% during the third quarter. Assenagon Asset Management S.A. now owns 453,579 shares of the medical instruments supplier’s stock valued at $47,762,000 after acquiring an additional 418,470 shares during the last quarter. William Blair Investment Management LLC bought a new stake in Haemonetics during the second quarter valued at $24,906,000. Bank of New York Mellon Corp acquired a new stake in Haemonetics during the 2nd quarter worth about $21,566,000. Finally, Dimensional Fund Advisors LP grew its holdings in Haemonetics by 21.3% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier’s stock worth $74,731,000 after acquiring an additional 233,119 shares during the period. Institutional investors own 99.67% of the company’s stock.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Fiscal Q2 adjusted earnings of $1.35 per share topped the $1.29 consensus, while revenue of $357.8 million exceeded estimates of $345.2 million and rose 9.4% year over year. Haemonetics reports Q2 results
• Positive Sentiment: The company raised its fiscal 2027 revenue and organic-growth outlook, forecasting organic growth of 6%–9%. It also expects to continue scaling the CSL Persona PLUS rollout through calendar 2027. FY 2027 growth outlook
• Positive Sentiment: Barrington Research raised its price target to $145 and maintained an “outperform” rating; BTIG Research raised its target to $142 and reiterated “buy.” These target increases signal continued analyst confidence after the results. Barrington Research target increase
• Neutral Sentiment: The earnings-call coverage highlighted growth-versus-margin trade-offs. That may temper enthusiasm if investors focus on the costs or profitability effects of scaling the business and product rollout. Earnings call highlights

About Haemonetics

Haemonetics Corporation (NYSE: HAE) is a healthcare technology company that develops and supplies products and services for blood and plasma collection, processing, and management. Its solutions are used by blood and plasma collection organizations, hospitals, and other healthcare providers to support the efficient handling of blood components and improve patient care.

The company’s offerings include automated plasma and blood-component collection systems, disposable collection sets, blood-processing equipment, and software designed to manage collection and transfusion-related operations.